Mechanisms of sensory dysfunction in diabetic neuropathy

Abstract

Sensory loss is a major symptom of diabetic neuropathy and a characteristic feature of ageing. Sensory changes in ageing and diabetes start distally in the longest sensory afferents, progress proximally over time and are likely to have common aetiologies in metabolic factors such as reactive oxygen species, glycating agents and neuroinflammation. During this studentship, we will elucidate the mechanisms responsible for diabetic sensory neuropathy and the maintenance of normal sensory function. Streptozotocin (STZ) induced diabetes is the most commonly used animal model of diabetes and diabetic complications. We recently showed that STZ produces TRPA1 mediated sensory changes BEFORE the onset of diabetes, which cannot be distinguished from those associated with diabetic neuropathy. We will avoid STZ by using the Ins2/Akita strain of diabetic mice, a more refined model with improved translational validity (3Rs). We have C57BL/6J Akita (suitable for crossing with transgenic strains) and have characterized the time course of sensory changes in several modalities. The most striking abnormalities are reduced mechanical and cold sensitivities. The student will also determine whether the Ins2/Akita strain develops apparent cognitive deficits in learning and memory tasks and whether brains and DRGs from diabetic Ins2/Akita mice exhibit signs of neuroinflammation.

Publications

10 25 50

Studentship Projects

Project Reference Relationship Related To Start End Student Name
BB/M009513/1 01/10/2015 31/03/2024
1879552 Studentship BB/M009513/1 01/10/2016 30/03/2021 Nurjahan Saleque
 
Description I have used a unique electrophysiological technique which has shed light on the cellular mechanisms involved in oxaliplatin-induced cold hypersensitivities and dysaesthesias. I have shown that a few classes of sensory neurons which are not usually cold sensitive are recruited to become cold sensitive after application of oxaliplatin to the skin-saphenous nerve preparation. This has enabled further investigations into understanding the molecular mechanisms that are involved. I was able to identify a novel ion channel target based on high throughput screening methods and validate this in our in vivo and in vitro models. This means that there may be an additional target involved in the effects of oxaliplatin.
Exploitation Route This novel target in the mechanism may allow adjuvant therapies to be used alongside oxaliplatin in order to minimise the side effects of the anticancer drug.
Sectors Healthcare,Pharmaceuticals and Medical Biotechnology